Drug-eluting stents

Optimal Stent Design for High Bleeding Risk Patients: Evidence From a Network Meta-Analysis

03/01/2021

Juan G. Chiabrando, MD^1,2,3; Giovanni M. Vescovo, MD⁴;
Marco Giuseppe Del Buono, MD⁵; Marco Lombardi, MD⁵;
Massimiliano Camilli, MD⁵; Krishna Ravindra, MD¹;
Rocco Antonio Montone, MD^5,6; Giampaolo Niccoli, MD^5,6;
Giuseppe Biondi-Zoccai, MD, MStat^7,8

Juan G. Chiabrando, MD1,2,3; Giovann...

Polymer-free (PF) drug-eluting stent (DES) devices have a proven benefit over bare-metal stent (BMS) devices in previous trials. It is unknown, however, whether polymer-based (PB)-DES devices are as safe as PF-DES devices.

Polymer-free (PF) drug-eluting...

03/01/2021

Journal of Invasive Cardiology

Calcium Corner

Three-Year Data From BIOFLOW V: The Orsiro vs the Xience Drug-Eluting Stents

05/11/2020

CLD talks with David E. Kandzari, MD, Director of Interventional, Piedmont Heart Institute and Chief Scientific Officer, Piedmont Healthcare, Atlanta, Georgia.

CLD talks with David E. Kandzari, MD,...

The 3-year data have shown us a continued, highly significant statistically but also very clinically meaningful difference in the outcomes of target vessel-related myocardial infarction, target lesion revascularization, and the composite of...

The 3-year data have shown us a...

05/11/2020

Cath Lab Digest

Plaque Sealing With Drug-Eluting Stents Versus Medical Therapy for Treating Intermediate Non-Obstructive Saphenous Vein Graft Lesions: A Pooled Analysis of the VELETI and VELETI II Trials

10/29/2019

Frédéric Maes, MD, PhD¹; Sanjit S. Jolly, MD²; John Cairns, MD³; Robert Delarochellière, MD¹; Mélanie Côté, MSc¹; Vladimir Dzavik, MD⁴; Josep Rodés-Cabau, MD¹

Frédéric Maes, MD, PhD1; Sanjit S. J...

The presence of intermediate “non-obstructive” saphenous vein graft lesions is a strong predictor of cardiac events. Our study aims to assess the efficacy of sealing these saphenous vein graft lesions with drug-eluting stent implantation for...

The presence of intermediate...

10/29/2019

Journal of Invasive Cardiology

Resolute Onyx 2.0: A New Tool for Small Vessel Coronary Artery Disease

09/05/2019

Jeffrey B. Ai, EMT, University of Minnesota, Minneapolis, Minnesota, Zhaowei Ai, MD, PhD, FACC, Prevea Health, Green Bay, Wisconsin

Jeffrey B. Ai, EMT, University of Min...

It is estimated that 65% of extra-small vessels are located in critical locations of the heart.8

It is estimated that 65% of...

09/05/2019

Cath Lab Digest

Long-Term Clinical Safety and Efficacy: The Orsiro Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stent

06/07/2019

Cath Lab Digest talks with David E. Kandzari, MD, Director of Interventional Cardiology and Cardiovascular Research, Piedmont Heart Institute, Atlanta, Georgia.

Cath Lab Digest talks with David E. K...

Can you describe the Orsiro stent?

Can you describe the Orsiro...

06/07/2019

Cath Lab Digest

The Incidence of Non-Cardiac Surgery in Patients Treated With Drug-Eluting Stents According to Age

01/30/2019

Oh-Hyun Lee, MD¹; Sung-Jin Hong, MD^₂; Chul-Min Ahn, MD²; Jung-Sun Kim, MD^2,3; Byeong-Keuk Kim, MD^2,3; Young-Guk Ko, MD^2,3; Donghoon Choi, MD^2,3; Yangsoo Jang, MD^2,3,4; Myeong-Ki Hong, MD^2,3,4

Oh-Hyun Lee, MD1; Sung-Jin Hong, MD2...

We evaluated the incidence and timing of non-cardiac surgery after drug-eluting stent implantation according to patient age.

We evaluated the incidence and...

01/30/2019

Journal of Invasive Cardiology

News

News: Onyx 1-Month OCT Study Provides Potential Insights on DAPT Duration in Complex Patients Following Stent Implantation

05/28/2018

Investigators unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early vessel healing in a patient population with a high percentage of patients with complex coronary artery disease who were implanted with...

Investigators unveiled clinical...

05/28/2018

Cath Lab Digest

News

News: Xience Sierra, Newest Generation of Xience Drug-Eluting Stents, Receives U.S. Food and Drug Administration (FDA) Approval

05/28/2018

Design innovations in Xience Sierra include a thinner profile, increased flexibility, longer lengths, and small diameters.

Design innovations in Xience...

05/28/2018

Cath Lab Digest

"Candy Cane" Guide Catheter Extension for Stent Delivery

07/30/2015

Theodoros I. Repanas, MD; Georgios Christopoulos, MD; Emmanouil S. Brilakis, MD, PhD

Theodoros I. Repanas, MD; Georgios C...

Stent delivery to a native coronary artery lesion located proximal to the anastomosis of a bypass graft can be challenging due to severe tortuosity. Guide catheter extensions such as the GuideLiner can facilitate equipment delivery, as...

Stent delivery to a native...

07/30/2015

Journal of Invasive Cardiology

Original Contribution

Biolimus-A9 Eluting Stent Implantion for Unprotected Left Main Coronary Artery Stenosis: 9-Month Strut Coverage as Assessed by Optical Coherence Tomography

02/01/2015

Nevio Taglieri, MD; Gabriele Ghetti, MD; Francesco Saia, MD, PhD; Carolina Moretti, MD; Pamela Gallo, MD;

Gianni Dall‚ÄôAra; Tullio Palmerini, MD; Cinzia Marrozzini, MD; Claudio Rapezzi, MD; Antonio Marzocchi, MD

Nevio Taglieri, MD; Gabriele Ghetti,...

Incomplete stent strut coverage is a risk factor for late stent thrombosis. This study evaluates strut coverage after biolimus-A9 eluting stent (BES) implantation for unprotected left main artery (ULMA) stenosis during follow-up and identify...

Incomplete stent strut coverage...

02/01/2015

Journal of Invasive Cardiology